Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg IFNα-2b + Targeted Immunotherapy in Advanced HBV-HCC
NCT07769827Recruiting
- Sponsor
- Jinling Hospital
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Open-label, single-arm trial of peginterferon alfa-2b in hepatocellular carcinoma (HCC) and hepatitis B (HBV), sponsored by Jinling Hospital. Primary endpoints: Progression-Free Survival at 1 year and Overall Survival at 36 months. Started Dec 2025; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT07769827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07769827.